Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Medivir B (MVRBF)

Medivir B (MVRBF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow 5.96
  • Price/Book 1.88
Trade MVRBF with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2000 unch
on 09/21/21
1.3000 -7.69%
on 09/10/21
+0.0100 (+0.84%)
since 08/16/21
3-Month
0.9000 +33.33%
on 07/15/21
1.3000 -7.69%
on 09/10/21
+0.0940 (+8.50%)
since 06/15/21
52-Week
0.8600 +39.53%
on 02/04/21
1.7500 -31.43%
on 10/27/20
-0.4300 (-26.38%)
since 09/14/20

Most Recent Stories

More News
Medivir receives regulatory approval from MHRA for phase 1/2a combination study with MIV-818

/PRNewswire/ -- (Nasdaq Stockholm: MVIR) today announced that the company has received regulatory approval from the British Medicines & Healthcare products Regulatory Agency (MHRA) for its upcoming phase...

MVRBF : 1.2000 (-1.68%)
IGMS : 73.64 (unch)
Medivir AB - Interim Report January - June 2021

HUDDINGE, , /PRNewswire/ --

MVRBF : 1.2000 (-1.68%)
Medivir strengthens the business development potential of remetinostat through renegotiated multi-party agreement

HUDDINGE, , /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that Medivir AB ("Medivir" or "the Company") together with the originators of remetinostat, and TetraLogic Pharmaceuticals...

MVRBF : 1.2000 (-1.68%)
IGMS : 73.64 (unch)
Positive data from the remetinostat phase II study in basal cell carcinoma published in Clinical Cancer Research

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that positive data from the investigator-initiated study evaluating the effects of remetinostat in basal cell carcinoma (BCC) patients...

MVRBF : 1.2000 (-1.68%)
IGMS : 73.64 (unch)
Respiratory Syntactical Virus (RSV) Market Size, Share, Trends, Analysis and Forecast 2027

The report on Respiratory Syntactical Virus (RSV) provides the clients with a comprehensive analysis of crucial driving factors, consumer behavior, growth trends, product utilization, key player analysis,...

ABT : 125.13 (+0.21%)
ABBV : 107.15 (+0.70%)
AZN : 59.13 (+1.08%)
GILD : 71.73 (+1.09%)
GSK : 39.08 (+0.59%)
HOLX : 76.44 (-0.38%)
LMNX : 36.99 (+0.03%)
MVRBF : 1.2000 (-1.68%)
MRK : 71.97 (+0.06%)
VRX.TO : 30.80 (-3.33%)
Medivir appoints Malene Jensen as VP Clinical Development

/PRNewswire/ -- announced today it has appointed as Vice President Clinical Development. She will assume her role as VP Clinical Development after the summer, at the latest . will also join the company's...

0GP7.LN : 9.990 (-9.18%)
MVRBF : 1.2000 (-1.68%)
IGMS : 73.64 (unch)
Medivir to present at the ABGSC Life Science Summit

, /PRNewswire/ --  announces that the company will present at the virtual meeting ABGSC Life Science Summit, today, .The company will be represented by, interim CEO, and Fredrik �berg, Chief Scientific...

0GP7.LN : 9.990 (-9.18%)
MVRBF : 1.2000 (-1.68%)
IGMS : 73.64 (unch)
Medivir AB - Interim Report January - March 2021

HUDDINGE, , /PRNewswire/ --

MVRBF : 1.2000 (-1.68%)
Medivir to participate at the Kempen Life Sciences Conference

, /PRNewswire/ --

MVRBF : 1.2000 (-1.68%)
IGMS : 73.64 (unch)
Medivir has determined the starting dose for the next part of the phase Ib study with MIV-818

, /PRNewswire/ --  today announced that the last patient has undergone the safety follow-up to identify potentially dose-limiting toxicity from the first part of the phase Ib study with the company's...

MVRBF : 1.2000 (-1.68%)

Key Turning Points

3rd Resistance Point 1.2000
2nd Resistance Point 1.2000
1st Resistance Point 1.2000
Last Price 1.2000
1st Support Level 1.2000
2nd Support Level 1.2000
3rd Support Level 1.2000

See More

52-Week High 1.7500
Fibonacci 61.8% 1.4100
Fibonacci 50% 1.3050
Fibonacci 38.2% 1.2000
Last Price 1.2000
52-Week Low 0.8600

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar